New York, Jan 15, 2026, 19:27 EST — After-hours
- J&J shares nudged up in extended trading after a volatile session.
- The drugmaker flagged new late-stage data for Tecvayli in multiple myeloma.
- Investors are circling the Jan. 21 results and 2026 outlook.
Johnson & Johnson shares (JNJ.N) rose about 0.5% in after-hours trading on Thursday to $219.57, after swinging between $215.93 and $219.73 during the regular session.
The healthcare conglomerate is set to report fourth-quarter results on Jan. 21, with Chief Executive Joaquin Duato and Chief Financial Officer Joseph Wolk scheduled to lead an 8:30 a.m. ET conference call. Guidance for 2026 is likely to do most of the work on the day.
Late on Wednesday, the company said its Phase 3 MajesTEC-9 study of Tecvayli (teclistamab) showed a 71% reduction in the risk of disease progression or death and a 40% reduction in the risk of death versus standard regimens in relapsed or refractory multiple myeloma. “The impressive results show a significant improvement in progression-free and overall survival,” said Roberto Mina, an Emory University associate professor; J&J oncology executive Yusri Elsayed said the drug “continues to break new ground.” The company said it will present full results at a future major medical meeting and share them with health authorities. JNJ.com
On Thursday, J&J also announced a U.S. launch of a mobile 3D simulation app for its Mentor breast augmentation business, aimed at helping surgeons and patients visualize potential outcomes during consultations. “By allowing them to visualize potential outcomes in seconds, this app brings clarity,” said Alenka Brzulja, worldwide president of aesthetics and reconstruction at J&J MedTech. JNJ.com
The backdrop is an earnings season that investors want to carry a market that has been leaning hard on company outlooks, with Washington headlines still noisy. “The most important thing right now is earnings,” Chris Fasciano, chief market strategist at Commonwealth Financial Network, told Reuters; U.S. stock markets are closed Monday for the Martin Luther King Jr. holiday, compressing next week’s schedule. Reuters
For J&J, the near-term focus stays split: drugs in its Innovative Medicine unit, and devices in MedTech. Pipeline updates can move the needle, but the stock tends to take its cues from what management says about demand, pricing and the pace of new launches.
In blood cancers, the race is crowded. Pfizer’s Elrexfio is among the U.S.-approved BCMA-directed bispecific antibodies in multiple myeloma, keeping pressure on pricing and positioning as companies try to move treatments earlier in care.
But the downside case is easy to sketch. Trial headlines are topline until full data land, regulators can ask for longer follow-up, and immune-engaging therapies can carry safety burdens that limit uptake outside specialist centers.
For the next session, traders will watch whether J&J holds Thursday’s late bid and whether interest in defensives stays steady into a holiday-shortened week. The real catalyst is Jan. 21, when J&J reports before the bell and lays out its 2026 view.
